Australia's largest stock trading and investment forum Australia's #1 stock forum

ACW

3.85%

2.7¢ actinogen medical limited

Ann: Review of 2019 and outlook, page-35

First 35 Last

Share
Profile

Follow
tls78

611 Posts.

75

20/12/19

10:35

Post #: 42066426
Share

Originally posted by Stungun: ↑

I particularly like the target group for the next trial. This group may well set them up for positive results similar to Xanahes and then possibly we will have a drug for the wider population. In the AGM presentation Dr Ketelby mentions funding applications locally and internationally which I didn't know about (Internationally). Christmas and New Year is the worst time of the yr to get anything done and The cogs turn slowly due to the field ACW are in (medicine) especially when humans are the guinea pigs. The trial is being prepared for the FDA approval by the advisory board. I was encouraged when some males in the Xanadu trial showed some positive signals in the minor cognitive tests at 10 mg, so that is promising and is better than nothing (which confirms to me that the dose was too low imo). The sinking share price is painful but I trust the board, executive and advisory board. Dr Ketelby has always responded to my emails promptly and honestly so don't be frightened to contact him if you have concerns. I believe the additional studies set up to run along with Xanadu were undertaken as they knew 10mg was too low which has put us back for at least another 12 months minimum. From a future patient or recipient of Xamamen wishing every one a Merry Christmas and a prosperous New Year and good health.

Expand

agree mate - christmas/new year is a slow time of year period.

ACW Price at posting: 3.4¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

What's causing the cost-of-living crisis, and how to navigate it

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon